[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"invasive-pulmonary-aspergillosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:invasive-pulmonary-aspergillosis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,68,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100617046","pcr-for-aspergillus-fumigatus-in-blood-and-bronchoalveolar-lavage-fluid-for-monitoring-cases-of-invasive-aspergillosis-what-is-its-prognostic-value-100617046",false,"NCT07313527","PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value","ASP","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Positive Aspergillus fumigatus PCR on serum or bronchoalveolar lavage fluid at diagnosis, performed at the Strasbourg University Hospital between January 1, 2017, and December 31, 2024.\n\nExclusion Criteria:\n\n* No subsequent Aspergillus fumigatus PCR (\\>24h)\n* No diagnosis of probable or proven invasive aspergillosis (EORTC\u002FMSGERC 2020 criteria)\n* Effective antifungal treatment against Aspergillus initiated before the first PCR\n* Death \\\u003C72h after starting antifungal treatment","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Aspergillus fumigatus PCR is currently used in conjunction with serum galactomannan to support the diagnosis of invasive aspergillosis or for monitoring at-risk patients not receiving antifungal prophylaxis. A positive result and a high titer are thought to be associated with the advanced stage of the disease and the fungal load. However, there is limited data on this subject, and no study has primarily focused on the variation of PCR levels during treatment and its potential correlation with treatment efficacy.",[24],"Invasive Pulmonary Aspergillosis",[24,26,27],"Aspergillus fumigatus PCR","Bronchoalveolar lavage fluid","RECRUITING","2025-12-17",{"date":31,"type":32},"2026-01-02","ACTUAL",{"date":34,"type":32},"2025-03-17",{"date":36,"type":20},"2026-02",{"name":38,"class":39},"University Hospital, Strasbourg, France","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100343163","influenza-associated-aspergillosis-in-depth-investigation-100343163","NCT03748069","Influenza Associated Aspergillosis In-depth Investigation","Unraveling the Pathogenesis of Influenza-associated Aspergillosis: a Single-center, Prospective Cohort Pilot Study","PIAS","Inclusion Criteria:\n\n* All patients older than 18 years, admitted to ICU with respiratory distress with microbiologically confirmed diagnosis of influenza (for inclusion in the influenza group)\n* All patients older than 18 years, admitted to ICU for respiratory distress due to community- acquired pneumonia , with a microbiologically confirmed absence of influenza (for inclusion in the control group)\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Pregnant women\n* No informed consent",{"count":50,"type":20},45,"This trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients in ICU.",[53,24],"Influenza With Pneumonia",[55,56,57,58],"Influenza","IPA","ICU","Immunology","2025-11-14",{"date":61,"type":32},"2025-11-17",{"date":63,"type":32},"2019-01-18",{"date":65,"type":20},"2027-04",{"name":67,"class":39},"Universitaire Ziekenhuizen KU Leuven",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":40},"100557408","breath-analysis-for-the-detection-of-invasive-fungal-infections-100557408","NCT06537726","Breath Analysis for the Detection of Invasive Fungal Infections","Real-time Breath Analysis for the Detection of Invasive Fungal Infections in Neutropenic High-risk Patients","REDEFINE","Inclusion Criteria:\n\n* Diagnosis of acute leukemia\n* Planned chemotherapy with a duration of hospitalisation of 2 weeks or longer\n* Neutropenia (\\\u003C500\u002Fµl) present at inclusion or planned chemotherapy with expected neutropenia (\\\u003C500\u002Fµl) for more than 7 days\n\nExclusion Criteria:\n\n* Unable to follow instructions for breath analysis\n* Anatomic abnormalities precluding the use of a mouthpiece for breath analysis",{"count":77,"type":20},130,"Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity.\n\nWith the present study, the investigators aim to determine a set of specific volatile biomarkers in leukemia patients with proven or probable IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).",[80,81,82,83,84,85,24],"Leukemia","Leukemia, Myeloid","Leukemia, Lymphoblastic","Neutropenia","Chemotherapy-induced Neutropenia","Invasive Fungal Infections","2025-04-09",{"date":88,"type":32},"2025-04-10",{"date":90,"type":32},"2024-08-19",{"date":92,"type":20},"2027-10-31",{"name":94,"class":39},"University of Zurich",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100505363","early-diagnosis-of-invasive-lung-aspergillosis-100505363","NCT05860387","Early Diagnosis of Invasive Lung Aspergillosis","Inclusion Criteria:\n\n* respiratory rate ≥ 30 breaths\u002Fmin\n* PaO2\u002FFiO2 ratio ≤ 250\n* multilobar infiltrates\n* confusion\u002Fdisorientation\n* uremia (blood urea nitrogen level ≥ 20mg\u002FdL)\n* leucocytosis (white blood cell count \\> 12000\u002FmL) or\n* leukopenia (white blood cell count \\\u003C 4 x 109\u002FL)\n* thrombocytopenia (platelet count \\\u003C 100 x 109\u002FL)\n* hyperthermia (core temperature \\> 38 °C)\n* hypothermia (core temperature \\\u003C 36 °C)\n* hypotension requiring aggressive fluid resuscitation\n* invasive mechanical ventilation and septic shock requiring vasopressors\n* Bronchoalveolar Lavage Fluid (BALF) and\u002For Endotracheal Aspirate (ETA)\n\nExclusion Criteria:\n\n\\- patients, in whom PTX3, Aspergillus qPCR, and HPLC-FTICR were not performed or were performed after the start of antifungal treatment",{"count":102,"type":20},150,"The last decade has seen a significant increase in secondary Aspergillus infections, not only due to primary hypersensitivity, and immunodeficiency based on oncological diseases and their therapy, but mainly due to a rise in severe respiratory infections (H1N1, COVID-19, bacterial infections). This is most evident in critically ill patients whose life is threatened by invasive pulmonary aspergillosis (IPA), with over 90 % of cases being caused by Aspergillus fumigatus. In recent decades, various biomarkers with well-known limits of use (Aspergillus DNA, galactomannan, 1,3-ß-D-glucan) have been used for early diagnosis of IPA. However, the clinical need to clearly distinguish the onset of IPA from colonization is much more significant. The current biomarkers only provide \"probable IPA\" interpretation, and the diagnosis is rarely confirmed. Based on our preliminary studies, the use of new low molecular weight substances (secondary metabolites) combined with acute-phase proteins (pentraxin 3) allows very reliable immediate confirmation of IPA. In tissue samples, bronchoalveolar lavage fluid, endotracheal aspirate, breath condensate, serum, and urine of critically ill patients, the investigators will be able to recognize and confirm IPA in time using highly sensitive mass spectrometry detecting specific microbial siderophores in correlation with a significantly increased concentration of acute-phase host protein (pentraxin 3) within hours of the beginning of the invasion of lung tissue. Through a prospective multicentre study, the investigators will evaluate the benefit of new biomarkers in non-invasive IPA confirmation, improve the IPA diagnostic algorithm and transfer the detection method to MALDI-TOF spectrometers widely used in Clinical laboratories in the Czech Republic. In MALDI-TOF mass spectrometry, the ion source is matrix-assisted laser desorption\u002Fionization (MALDI), and the mass analyser is a time-of-flight (TOF) analyser.\n\nThe study results will contribute to a high clarity of IPA cases, the accurate introduction of antifungal therapy, and a better prognosis of survival of critically ill patients.",[105,24],"Respiratory Infection",[107,108,109,110,111,112,113],"biomarkers","qualitative polymerase chain reaction (qPCR)","metallomics","mass spectrometry","colonisation","invasive pulmonary aspergillosis","Pentraxin-3","2023-09-06",{"date":116,"type":32},"2023-09-07",{"date":118,"type":32},"2023-05-31",{"date":120,"type":20},"2026-12-31",{"name":122,"class":39},"University Hospital Ostrava",7]